BR112017010700A2 - combinação de ibudilaste e riluzol e métodos de uso da mesma - Google Patents
combinação de ibudilaste e riluzol e métodos de uso da mesmaInfo
- Publication number
- BR112017010700A2 BR112017010700A2 BR112017010700A BR112017010700A BR112017010700A2 BR 112017010700 A2 BR112017010700 A2 BR 112017010700A2 BR 112017010700 A BR112017010700 A BR 112017010700A BR 112017010700 A BR112017010700 A BR 112017010700A BR 112017010700 A2 BR112017010700 A2 BR 112017010700A2
- Authority
- BR
- Brazil
- Prior art keywords
- ibudilaste
- riluzole
- methods
- combination
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title 1
- 229960004181 riluzole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084879P | 2014-11-26 | 2014-11-26 | |
| PCT/US2015/062456 WO2016085998A1 (en) | 2014-11-26 | 2015-11-24 | Combination of ibudilast and riluzole and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017010700A2 true BR112017010700A2 (pt) | 2018-05-08 |
Family
ID=56074979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010700A BR112017010700A2 (pt) | 2014-11-26 | 2015-11-24 | combinação de ibudilaste e riluzol e métodos de uso da mesma |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10258611B2 (enExample) |
| EP (1) | EP3223815B1 (enExample) |
| JP (1) | JP6827924B2 (enExample) |
| KR (1) | KR102462638B1 (enExample) |
| CN (1) | CN107205986A (enExample) |
| BR (1) | BR112017010700A2 (enExample) |
| CA (1) | CA2967826C (enExample) |
| ES (1) | ES2891306T3 (enExample) |
| WO (1) | WO2016085998A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021530543A (ja) * | 2018-07-22 | 2021-11-11 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | アルツハイマー病を処置するためのリルゾールプロドラッグの使用 |
| CN112584831A (zh) * | 2018-08-16 | 2021-03-30 | 拜奥海芬治疗学有限公司 | 利鲁唑口腔崩解片用于治疗疾病的用途 |
| ES2970996T3 (es) | 2018-10-19 | 2024-06-03 | Medicinova Inc | Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast |
| EP4031135A4 (en) | 2019-09-20 | 2023-10-18 | Icahn School of Medicine at Mount Sinai | CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| JP2024528731A (ja) | 2021-07-26 | 2024-07-30 | メディシノバ・インコーポレイテッド | 眼癌転移を予防するためのイブジラスト |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
| US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
| CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2375874A1 (en) | 1999-06-04 | 2000-12-14 | Chris Polman | Use of riluzole for the treatment of multiple sclerosis |
| WO2004105756A2 (en) | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| WO2006063048A2 (en) | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
-
2015
- 2015-11-24 US US15/527,280 patent/US10258611B2/en active Active
- 2015-11-24 ES ES15863670T patent/ES2891306T3/es active Active
- 2015-11-24 KR KR1020177015476A patent/KR102462638B1/ko active Active
- 2015-11-24 CN CN201580064290.9A patent/CN107205986A/zh active Pending
- 2015-11-24 CA CA2967826A patent/CA2967826C/en active Active
- 2015-11-24 BR BR112017010700A patent/BR112017010700A2/pt not_active Application Discontinuation
- 2015-11-24 EP EP15863670.4A patent/EP3223815B1/en active Active
- 2015-11-24 JP JP2017527621A patent/JP6827924B2/ja active Active
- 2015-11-24 WO PCT/US2015/062456 patent/WO2016085998A1/en not_active Ceased
-
2019
- 2019-02-28 US US16/289,636 patent/US20200030301A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,911 patent/US11278531B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017535569A (ja) | 2017-11-30 |
| ES2891306T3 (es) | 2022-01-27 |
| US10258611B2 (en) | 2019-04-16 |
| KR102462638B1 (ko) | 2022-11-03 |
| US20170360762A1 (en) | 2017-12-21 |
| US20210000804A1 (en) | 2021-01-07 |
| US20200030301A1 (en) | 2020-01-30 |
| KR20170086058A (ko) | 2017-07-25 |
| CA2967826C (en) | 2024-01-16 |
| CA2967826A1 (en) | 2016-06-02 |
| CN107205986A (zh) | 2017-09-26 |
| JP6827924B2 (ja) | 2021-02-10 |
| EP3223815A4 (en) | 2018-06-27 |
| WO2016085998A1 (en) | 2016-06-02 |
| EP3223815B1 (en) | 2021-07-28 |
| US11278531B2 (en) | 2022-03-22 |
| EP3223815A1 (en) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| IL278080A (en) | Riluzole prodrugs and their use | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| HRP20181742T1 (hr) | Hidroksialkil-supstituirani derivati feniltriazola i njihova uporaba | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PT3218005T (pt) | Compostos que interagem com glicano e métodos de uso | |
| HUE046000T2 (hu) | Antiproferatív vegyületek és alkalmazásuk módszerei | |
| IL263680A (en) | Combination therapies | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| CL2016002364A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas | |
| SI3518783T1 (sl) | Naprava za zmanjševanje tkiva | |
| IL247262B (en) | Cannabinoid compositions and uses | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| EP3205103C0 (en) | INTER AND INTRA UNIFICATION BLOCK COPY | |
| BR112016030968A2 (pt) | análogos de pridopidina, preparação e uso destes | |
| PT3215532T (pt) | Anticorpos anti-tim3 e métodos de utilização | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| HUE057607T2 (hu) | Pirazol-pirimidin-származék és annak felhasználása | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| MA41997A (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
| BR112016020889A2 (pt) | variantes de hppd e métodos de uso | |
| BR112017000895A2 (pt) | componente de mancal, mancal, uso de um componente de mancal, e uso de um mancal | |
| PL3457851T3 (pl) | Pochodne sobetiromu | |
| PL3411021T3 (pl) | Nowe zastosowanie kombinacji sakubitrylu i walsartanu | |
| IL250173B (en) | Actuation mechanism and associated methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |